1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Branded Generics Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Prevalence of chronic diseases necessitating the use of generic medications
5.1.1.2. Increasing patent expiration for blockbuster drugs and the need for cost-effective alternatives
5.1.2. Restraints
5.1.2.1. Concerns associated with quality variations in branded generic medications
5.1.3. Opportunities
5.1.3.1. Novel bioequivalence studies and efforts by market players to expand branded generics business
5.1.4. Challenges
5.1.4.1. Litigation issues and issues related to price erosion of innovator drugs
5.2. Market Segmentation Analysis
5.2.1. Product: Significant adoption of value-added branded generics due to their additional advantages
5.2.2. Drug Type: High usage of anti-hypertensive for treating high blood pressure
5.2.3. Route of Administration: Wide adoption of oral route due to their longer duration of action
5.2.4. Indication: Burgeoning utilization of branded generics for gastrointestinal diseases and neurological diseases
5.2.5. Distribution Channel: Evolving online distribution channels for branded generics
5.3. Market Trend Analysis
5.3.1. Availability of well-structured standards for branded generics in the Americas
5.3.2. Supportive government initiatives and growing need for affordable branded generic drugs in the Asia-Pacific region
5.3.3. Presence of well-established pharmaceutical companies emphasizing on expanding geographical reach of branded generics in the EMEA region
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Branded Generics Market, by Product
6.1. Introduction
6.2. Trade Named Generics
6.3. Value-Added
7. Branded Generics Market, by Drug Type
7.1. Introduction
7.2. Alkylating Agents
7.3. Anti-depressants
7.4. Anti-epileptics
7.5. Anti-hypertensive
7.6. Anti-psychotics
7.7. Antimetabolites
7.8. Hormones
7.9. Lipid Lowering Drugs
8. Branded Generics Market, by Route of Administration
8.1. Introduction
8.2. Oral
8.3. Parenteral
8.4. Topical
9. Branded Generics Market, by Indication
9.1. Introduction
9.2. Acute & Chronic Pain
9.3. Cardiovascular Diseases
9.4. Dermatological Diseases
9.5. Gastrointestinal Diseases
9.6. Neurological Diseases
9.7. Oncology
10. Branded Generics Market, by Distribution Channel
10.1. Introduction
10.2. Offline
10.3.1. Hospital Pharmacy
10.3.2. Retail Pharmacy
10.3. Online
11. Americas Branded Generics Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Branded Generics Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Branded Generics Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. FPNV Positioning Matrix
14.2. Market Share Analysis, By Key Player
14.3. Competitive Scenario Analysis, By Key Player
14.3.1. Merger & Acquisition
14.3.1.1. Zentiva Completes Major Product Acquisition From Tillomed Spain
14.3.1.2. Procaps Group to Acquire Grupo Somar from Advent International
14.3.2. Agreement, Collaboration, & Partnership
14.3.2.1. Pharmaceutical Alliance, Generic Pharmaceutical Association Renew Generic Drug Pricing Agreement
14.3.3. New Product Launch & Enhancement
14.3.3.1. Amneal Launches Authorized Generic for Xyrem (sodium oxybate) and Receives FDA Approval for Five Complex Generics
14.3.3.2. Sun Pharma Launches Generic Version of Pfizer’s Blockbuster Cancer Drug
14.3.3.3. Cipla Launches ‘Easylax L’,A Sugar-Free Oral Emulsion Laxative For Constipation Relief
14.3.4. Award, Recognition, & Expansion
14.3.4.1. Vyvanse Generics Approved by FDA
14.3.4.2. Ajanta Pharma looks to expand ops in high-growth Asian, African geographies
14.3.4.3. Dr Reddy’s Enters Trade Generics Business In Domestic Market
15. Competitive Portfolio
15.1. Key Company Profiles
15.1.1. Abbott Laboratories
15.1.2. Ajanta Pharma Ltd.
15.1.3. Alkem Laboratories Ltd.
15.1.4. Amneal Pharmaceuticals LLC
15.1.5. Apotex Inc.
15.1.6. Aspen Pharmacare Holdings Limited
15.1.7. AstraZeneca PLC
15.1.8. Aurobindo Pharma Limited
15.1.9. Bausch Health Companies Inc.
15.1.10. Bristol-Myers Squibb Company
15.1.11. Cipla Limited
15.1.12. Dr. Reddy’s Laboratories Ltd.
15.1.13. Endo International PLC
15.1.14. Eris Lifesciences Limited
15.1.15. Eva Pharma
15.1.16. Fresenius Kabi AG
15.1.17. GlaxoSmithKline PLC
15.1.18. Glenmark Pharmaceuticals Limited
15.1.19. Hetero Drugs Limited
15.1.20. Lupin Limited
15.1.21. Micro Labs Limited
15.1.22. Nichi-Iko Pharmaceutical Co., Ltd.
15.1.23. Pfizer Inc.
15.1.24. Sandoz International GmbH by Novartis AG
15.1.25. Sanofi S.A.
15.1.26. Sun Pharmaceutical Industries Ltd.
15.1.27. Teva Pharmaceutical Industries Ltd.
15.1.28. Torrent Pharmaceuticals Ltd.
15.1.29. Viatris Inc.
15.1.30. Zentiva Group, a.s.
15.2. Key Product Portfolio
16. Appendix
16.1. Discussion Guide
16.2. License & Pricing